Logo

Galapagos Signs Huntington Disease Research Deal with High Q Foundation

Aug 12, 2005

NEW YORK, Aug. 12 (GenomeWeb News) - Galapagos said today that it has signed a two-year target-discovery agreement with the High Q Foundation, a non-profit organization that supports Huntington disease research.

 

High Q and Galadeno, Galapagos' partnering unit, will use Galapagos' adenoviral siRNA and cDNA collections to discover and validate drug targets for the development of new Huntington disease therapies.

 

Galapagos said that it could ultimately receive up to $3 million from the High Q Foundation for the project. The company also has the option to develop certain targets identified in the program.

 

Galapagos said that the final agreement with High Q has not yet been signed, but that it expects to do so before Oct. 1.

 

The company signed a similar agreement with the Cystic Fibrosis Foundation in April.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.